Johnson & Johnson, its place in the healthcare and biotechnology sector and full sector report
Includes full sector report with 17 healthcare and biotechnology companies, where Johnson & Johnson is analysed in relative perspective of Abbott Laboratories, Abbvie, Amgen, AstraZeneca plc, Bayer AG, Biogen, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Merck, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healthcare and biotechnology sector and drives your outperformance. Targeted and expected outperformance is 10% per year on the upper half of companies and 5% per year on a diversified standard portfolio in the sector based on long term results and experience.
Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has three business segments: Consumer, which includes a range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension; and Medical Devices, which includes products used in the orthopaedic, surgery, interventional solutions, and eye health fields.
Analist is and analysis by drs. E. (Erik) D. Molenaar RBA, RBA/CFA certified investment analist and EFFAS certified financial analist. Delivering to the point investment analysis. Apart from an absolute advice, a clear sector advice and overview, and/or a relative advice within the sector, is always included in the reports which makes the reports extremely usefull and helpfull for fund allocation within a sector.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.